A proton gradient is the driving force for uphill transport of lactate in human placental brush-border membrane vesicles.
The characteristics of lactate transport in brush-border membrane vesicles isolated from normal human full-term placentas were investigated. Lactate transport in these vesicles was Na+-independent, but was greatly stimulated when the extravesicular pH was made acidic. In the presence of an inwardly directed H+ gradient ([H+]o greater than [H+]i), transient uphill transport of lactate could be demonstrated. This H+ gradient-dependent stimulation was not a result of a H+ diffusion potential. Transport of lactate in the presence of the H+ gradient was not inhibited by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid or by furosemide, ruling out the participation of an anion exchanger in placental lactate transport. Many monocarboxylates strongly interacted with the lactate transport system, whereas, with the single exception of succinate, dicarboxylates did not. The monocarboxylates pyruvate and lactate, but not the dicarboxylate succinate, when present inside the vesicles, were able to exert a trans-stimulatory effect on the uptake of radiolabeled lactate. Kinetic analyses provided evidence for a single transport system with a Kt of 4.1 +/- 0.4 mM for lactate and a Vmax of 54.2 +/- 9.9 nmol/mg of protein/30 s. Pyruvate inhibited lactate transport competitively, by reducing the affinity of the system for lactate without altering the maximal velocity. It is concluded that human placental brush-border membranes possess a transport system specific for lactate and other monocarboxylates and that this transport system is Na+-independent and is energized by an inwardly directed H+ gradient. Lactate-H+ symport rather than lactate-OH- antiport appears to be the mechanism of the H+ gradient-dependent lactate transport in these membranes.
Balkovetz
D F
DF
Department of Cell Biology, Medical College of Georgia, Augusta 30912.
Leibach
F H
FH
Mahesh
V B
VB
Ganapathy
V
V
D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid / Q000031:analogs & derivatives*; D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D000838:Anions; D001692:Biological Transport / Q000187:drug effects; D002264:Carboxylic Acids / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D007773:Lactates / Q000378:metabolism*; D019344:Lactic Acid; D008564:Membrane Potentials / Q000187:drug effects; D008871:Microvilli / Q000378:metabolism; D009550:Nigericin / Q000494:pharmacology; D010920:Placenta / Q000378:metabolism*; D011188:Potassium / Q000494:pharmacology; D011247:Pregnancy; D011522:Protons; D011773:Pyruvates / Q000494:pharmacology; D019289:Pyruvic Acid; D012964:Sodium / Q000494:pharmacology; D013386:Succinates / Q000378:metabolism / Q000494:pharmacology; D019802:Succinic Acid; D014634:Valinomycin / Q000494:pharmacology
D000838:Anions; D002264:Carboxylic Acids; D007773:Lactates; D011522:Protons; D011773:Pyruvates; D013386:Succinates; D014634:Valinomycin; D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; D019344:Lactic Acid; C018564:dihydro-DIDS; D005665:Furosemide; D019289:Pyruvic Acid; D012964:Sodium; D019802:Succinic Acid; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; D009550:Nigericin; D011188:Potassium